First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has exhibited substantial survival benefits in relapsed and refractory extensive-stage SCLC. Its efficacy in transformed SCLC, however, particularly in patients without actionable genetic alterations (AGA), remains largely unknown. Histologic t...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-05-01
|
| Seri Bilgileri: | JTO Clinical and Research Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2666364326000068 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|